US House Committee delays PDUFA changes
The US House of Representatives' Energy and Commerce Committee has delayed a meeting to "mark up" draft legislation to renew the Prescription Drug User Fee Act (Marketletters passim), following complaints from the minority-Republican members of the Health Subcommittee that decisions were being "rushed," the CongressDaily reports. A full mark up session of the committee will now be held on June 21.
The Senate has already passed legislation on the PDUFA, which contained a number of amendments that were considered favorable to the research-based sector (Marketletters passim), notably on direct-to-consumer advertising and the importation of prescription drugs from Canada. The Democrat-controlled House is expected to take a harder line than the upper chamber, where the Democrat majority is tiny: 51, including pro-Democrat independents, to 49 Republicans.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze